These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 15491144)
21. Vinaxanthone, a new FabI inhibitor from Penicillium sp. Zheng CJ; Sohn MJ; Kim WG J Antimicrob Chemother; 2009 May; 63(5):949-53. PubMed ID: 19282328 [TBL] [Abstract][Full Text] [Related]
22. The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli. Yogiara ; Mordukhova EA; Kim D; Kim WG; Hwang JK; Pan JG Bioorg Med Chem Lett; 2020 Dec; 30(24):127651. PubMed ID: 33130290 [TBL] [Abstract][Full Text] [Related]
23. Thermodynamic cycle analysis and inhibitor design against beta-lactamase. Roth TA; Minasov G; Morandi S; Prati F; Shoichet BK Biochemistry; 2003 Dec; 42(49):14483-91. PubMed ID: 14661960 [TBL] [Abstract][Full Text] [Related]
24. Structural basis and mechanism of enoyl reductase inhibition by triclosan. Stewart MJ; Parikh S; Xiao G; Tonge PJ; Kisker C J Mol Biol; 1999 Jul; 290(4):859-65. PubMed ID: 10398587 [TBL] [Abstract][Full Text] [Related]
25. Functional expression of Francisella tularensis FabH and FabI, potential antibacterial targets. Wen L; Chmielowski JN; Bohn KC; Huang JK; Timsina YN; Kodali P; Pathak AK Protein Expr Purif; 2009 May; 65(1):83-91. PubMed ID: 19095065 [TBL] [Abstract][Full Text] [Related]
26. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. Heath RJ; Rock CO J Biol Chem; 1995 Nov; 270(44):26538-42. PubMed ID: 7592873 [TBL] [Abstract][Full Text] [Related]
27. Crystal structures of Enoyl-ACP reductases I (FabI) and III (FabL) from B. subtilis. Kim KH; Ha BH; Kim SJ; Hong SK; Hwang KY; Kim EE J Mol Biol; 2011 Feb; 406(3):403-15. PubMed ID: 21185310 [TBL] [Abstract][Full Text] [Related]
28. Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK. Ozawa T; Kitagawa H; Yamamoto Y; Takahata S; Iida M; Osaki Y; Yamada K Bioorg Med Chem; 2007 Dec; 15(23):7325-36. PubMed ID: 17892940 [TBL] [Abstract][Full Text] [Related]
29. Signature gene expression profile of triclosan-resistant Escherichia coli. Yu BJ; Kim JA; Pan JG J Antimicrob Chemother; 2010 Jun; 65(6):1171-7. PubMed ID: 20410062 [TBL] [Abstract][Full Text] [Related]
30. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus. Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562 [TBL] [Abstract][Full Text] [Related]
31. Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase. Massengo-Tiassé RP; Cronan JE J Biol Chem; 2008 Jan; 283(3):1308-1316. PubMed ID: 18032386 [TBL] [Abstract][Full Text] [Related]
32. Characterization of the beta-carbon processing reactions of the mammalian cytosolic fatty acid synthase: role of the central core. Witkowski A; Joshi AK; Smith S Biochemistry; 2004 Aug; 43(32):10458-66. PubMed ID: 15301544 [TBL] [Abstract][Full Text] [Related]
33. Interaction of pyridine nucleotide substrates with Escherichia coli dihydrodipicolinate reductase: thermodynamic and structural analysis of binary complexes. Reddy SG; Scapin G; Blanchard JS Biochemistry; 1996 Oct; 35(41):13294-302. PubMed ID: 8873595 [TBL] [Abstract][Full Text] [Related]